Supportive Care (Studies)

Patients with a hematological, solid or brain malignancy,
4-18 years old before the start of treatment with chemotherapy
in the Princess Máxima Center.                                                             ENERGICE

Children with of all subtypes of cancer (aged 6-17 years),
currently treated with chemotherapy in the Princess Máxima
Center.                                                                                                   SENSORY

Patients aged 0-19 years who will receive
intravenously administered chemotherapy
and are treated with aprepitant and/or
dexamethasone plus granisetron/ondansetron
as standard of care, who will have a central line
in place to sample blood for PK.                                                           Aprepitant PK pilot

Patients aged between 2 and 18 years, having a
venous catheter (or blood is drawn for regular
patient care) who are treated with at least 1 of
the 9 drugs of interest.                                                                          PROTECT

Patients aged 3-18 years, treated according
to the medium risk ALL treatment schedule, 
in the second part of maintenance phase
(after cessation of asparaginase), with
clinically relevant dexamethasone induced
neurobehavioral side effects.                                                                DEXADagen-2

Participants (patients and healthy controls), at least
8 years old and able to undergo MRI without general
(Patients treated according to DCOG ALL-10
or ALL-11, and received ciprofloxacin during treatment).                      MRI Ciproxin